The study aims to find out if this combination can help the body tolerate the new liver, reducing the risk of the immune system attacking it, a condition known as liver allograft rejection. Participants in the study will receive the treatment and be monitored over a period of time to see if they can remain free from the usual medications that suppress the immune system. Some participants will receive a placebo instead of the active treatment to compare the results.

The study will last for up to 60 months, during which participants will undergo regular check-ups and tests to monitor their health and the function of the transplanted liver. The researchers will look at various outcomes, such as the number of patients who can stop taking immunosuppressive drugs and the occurrence of any complications like acute rejection of the liver. The ultimate aim is to improve the quality of life for liver transplant recipients by potentially reducing their dependence on long-term medication.

The purpose of this study is to monitor the safety and tolerability of the TX200-TR101 infusion over a long period. This means researchers will be looking at how well patients tolerate the treatment and whether there are any serious side effects. The study will also track the overall health and survival of the participants, as well as any instances of the transplanted kidney being rejected or not functioning properly.

Participants in this study are individuals who have previously received a kidney transplant and participated in an earlier phase of the study. The study will continue to follow these patients to gather more information about the long-term effects of the treatment. This research aims to provide valuable insights into the potential benefits and risks of using TX200-TR101 for managing kidney transplant rejection.

Participants in the study will be randomly assigned to receive either Envarsus or Advagraf after their liver transplant. The study will last for up to three years, with regular check-ups to monitor the levels of the medication in the blood and assess the health of the liver. The study will also track any side effects or complications that may arise during the treatment period. The aim is to find out which medication provides better control of drug levels, which can help improve the overall success of the liver transplant.

Throughout the study, participants will take their assigned medication once daily in the form of a prolonged-release tablet or capsule. This means the medication is designed to release slowly into the body over time, helping to maintain a steady level of the drug. The study will also look at how practical and easy it is for patients to take these medications as part of their daily routine. By comparing the two medications, researchers hope to provide valuable information that can help improve treatment options for liver transplant patients in the future.

The purpose of the study is to assess the safety and how well patients tolerate these medications over a period of 12 months after receiving a kidney transplant. Participants will receive either siplizumab or anti-thymocyte globulin, and their health will be monitored closely throughout the study. This includes regular check-ups and tests to understand how the medications are working in the body and to ensure that they are safe for use.

During the study, participants will be randomly assigned to receive either the investigational medication or the comparison medication. Some participants may also receive a placebo. The study will involve regular visits to the clinic for monitoring and assessments, which will help researchers gather important information about the effects of these treatments on kidney transplant patients. The goal is to find the best way to help prevent kidney rejection and improve the overall success of kidney transplants.

The purpose of the study is to evaluate the safety and tolerability of TX200-TR101 in patients who have received a kidney transplant. Participants in the study will receive a single dose of this treatment through an infusion, which means it will be delivered directly into the bloodstream. The study will monitor participants for any side effects or reactions to the treatment over a period of time, starting from the day of the infusion and continuing for several weeks.

Throughout the study, researchers will keep track of any health changes in the participants, including any signs of the body rejecting the kidney or other health issues. The study aims to gather information on how well the treatment works in helping the body accept the new kidney and whether it is safe for use in patients. This information will help determine if TX200-TR101 could be a beneficial treatment option for kidney transplant recipients in the future.

Participants in the study will take the Advagraf capsules orally, which means they will swallow them. The study will monitor the levels of tacrolimus in the blood over time to see how the body processes the medication. This will help determine if the new formulation maintains the necessary levels of the drug to prevent the body from rejecting the transplanted organ. The study will also keep track of any side effects or adverse events that may occur during the treatment period.

The study will include a long-term follow-up to assess the safety and effectiveness of Advagraf over an extended period. This means that participants will be observed for any changes in their health or any episodes of organ rejection. The goal is to ensure that the new formulation provides the same benefits as the previous one while being safe for long-term use in children who have undergone organ transplants.

Participants in the study will be adults who have undergone a kidney transplant. The study will involve taking one of the two medications once daily. The trial will last for a period of up to three years, during which various health parameters will be monitored. These include the levels of tacrolimus in the blood, kidney function, and any side effects experienced. The study will also look at how quickly patients reach the desired drug levels in their blood and how stable these levels remain over time.

The purpose of this study is to gather information that could help improve the management of kidney transplant patients by identifying the most effective and convenient medication regimen. By comparing Envarsus and Advagraf, researchers hope to provide valuable insights into which formulation offers better outcomes for patients in terms of drug absorption and overall health after a kidney transplant.

Participants in the study will be stable adult kidney transplant recipients who are considered to have a low risk of immune system complications in the first year after their transplant. The study will last for up to 36 months, during which time participants will receive either the standard tacrolimus treatment or a personalized dose based on their immune system’s response. The study aims to ensure that the personalized dosing is not inferior to the standard dosing in terms of safety and effectiveness.

Throughout the study, researchers will monitor various health outcomes, including any infections that require treatment, rejection of the transplanted kidney, and overall health and quality of life. The study will also track the levels of Torque Teno virus (TTV) in the blood, which is used to guide the personalized dosing of tacrolimus. The goal is to find a dosing strategy that maintains the health of the transplanted kidney while minimizing side effects and improving the patient’s quality of life.

The purpose of this study is to see how well these solutions work in preserving the liver during transplantation. Participants in the study will receive either Custodiol-N or Custodiol. The study will monitor the health of the liver after transplantation by measuring certain markers in the blood over a period of seven days. These markers include GPT (a liver enzyme), LDH (an enzyme that can indicate tissue damage), and other factors like bilirubin and INR (a measure of blood clotting).

Throughout the study, researchers will also look at other aspects of liver function and health, such as the occurrence of cholestasis (a condition where bile cannot flow from the liver to the duodenum), therapy for cholangitis (inflammation of the bile duct system), and any episodes of biliary leakage or strictures. The study aims to provide valuable information on which solution might be more effective in supporting liver health during and after transplantation.